Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03537599 · ClinicalTrials.gov registry record · Phase 1
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
A Phase 1 study, sponsored by Sumithira Vasu.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03537599 is a Phase 1 study that was terminated before completion, run by Sumithira Vasu. The registered enrollment target is 4 participants.
The verdict
NCT03537599, a Phase 1 study, was terminated before completion, sponsored by Sumithira Vasu.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of donor lymphocyte infusions when given together with daratumumab and to see how well they work in treating participants with acute myeloid leukemia that has come back after a stem cell transplant. A donor lymphocyte infusion is a type of therapy in which lymphocytes (white blood cells) from the blood of a donor are given to a participant who has already received a stem cell transplant from the same donor. The donor lymphocytes may kill remaining cancer cells. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Giving daratumumab and donor white blood cells may work better in treating participants with acute myeloid leukemia.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Daratumumab
- PROCEDURE Donor Lymphocyte Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2022-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03537599
The ClinicalTrials.gov registry entry for NCT03537599 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumithira Vasu, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03537599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03537599 about?
NCT03537599 is a clinical study titled "Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant". This phase I/II trial studies the side effects and best dose of donor lymphocyte infusions when given together with daratumumab and to see how well they work in treating participants with acute myeloid leukemia that has come back after a stem cell transplant. A donor lymphocyte infusion is a type of...
What is the current status of trial NCT03537599?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-01-10. Estimated completion is 2022-02-03.
What interventions are being tested in trial NCT03537599?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Daratumumab (BIOLOGICAL), Donor Lymphocyte Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT03537599?
This trial is sponsored by Sumithira Vasu, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.